Hanlon Peter, Fauré Isabella, Corcoran Neave, Butterly Elaine, Lewsey Jim, McAllister David A, Mair Frances S
Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
BMJ Open. 2020 Sep 1;10(9):e037476. doi: 10.1136/bmjopen-2020-037476.
Diabetes mellitus is common and growing in prevalence, and an increasing proportion of people with diabetes are living to older age. Frailty is, therefore, becoming an important concept in diabetes. Frailty is associated with older age and describes a state of increased susceptibility to decompensation in response to physiological stress. A range of measures have been used to quantify frailty. This systematic review aims to identify measures used to quantify frailty in people with diabetes (any type); to summarise the prevalence of frailty in diabetes; and to describe the relationship between frailty and adverse clinical outcomes in people with diabetes.
Three electronic databases (Medline, Embase and Web of Science) will be searched from 2000 to November 2019 and supplemented by citation searching of relevant articles and hand searching of reference lists. Two reviewers will independently review titles, abstracts and full texts. Inclusion criteria include: (1) adults with any type of diabetes mellitus; (2) quantify frailty using any validated frailty measure; (3) report the prevalence of frailty and/or the association between frailty and clinical outcomes in people with diabetes; (4) studies that assess generic (eg, mortality, hospital admission and falls) or diabetes-specific outcomes (eg, hypoglycaemic episodes, cardiovascular events, diabetic nephropathy and diabetic retinopathy); (5) cross-sectional and longitudinal observational studies. Study quality will be assessed using the Newcastle-Ottawa Scale for observational studies. Clinical and methodological heterogeneity will be assessed, and a random effects meta-analysis performed if appropriate. Otherwise, a narrative synthesis will be performed.
This manuscript describes the protocol for a systematic review of observational studies and does not require ethical approval.
CRD42020163109.
糖尿病很常见且患病率不断上升，患糖尿病的人群中活到老年的比例也在增加。因此，衰弱正成为糖尿病领域的一个重要概念。衰弱与老年相关，描述了一种因生理应激而更易失代偿的状态。一系列指标已被用于量化衰弱。本系统评价旨在确定用于量化糖尿病患者（任何类型）衰弱的指标；总结糖尿病患者中衰弱的患病率；并描述糖尿病患者衰弱与不良临床结局之间的关系。
将检索三个电子数据库（Medline、Embase和Web of Science）2000年至2019年11月期间的文献，并通过对相关文章的引文检索和参考文献列表的手工检索进行补充。两名评审员将独立评审标题、摘要和全文。纳入标准包括：（1）患有任何类型糖尿病的成年人；（2）使用任何经过验证的衰弱指标量化衰弱；（3）报告糖尿病患者中衰弱的患病率和/或衰弱与临床结局之间的关联；（4）评估一般结局（如死亡率、住院和跌倒）或糖尿病特异性结局（如低血糖发作、心血管事件、糖尿病肾病和糖尿病视网膜病变）的研究；（5）横断面和纵向观察性研究。将使用纽卡斯尔-渥太华量表评估观察性研究的质量。将评估临床和方法学异质性，若合适将进行随机效应荟萃分析。否则，将进行叙述性综述。
本手稿描述了一项观察性研究系统评价的方案，无需伦理批准。
PROSPERO注册号：CRD42020163109。
